HCV Treatment
AASLD 2014: Sustained Response to HCV Treatment Reduces Mortality, Liver Cancer, Liver Transplants
- Details
- Category: Approved HCV Drugs
- Published on Sunday, 09 November 2014 00:00
- Written by Liz Highleyman
People who achieve sustained virological response (SVR) when treated with interferon-based therapy for hepatitis C have a lower risk of death, are less likely to develop liver cancer, and need fewer liver transplants than those who were treated but not cured, according to results from a meta-analysis of more than 34,000 patients presented at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.
AASLD 2014: Sofosbuvir/Ledipasvir Cures Nearly All Genotype 1 HIV/HCV Coinfected Patients
- Details
- Category: Approved HCV Drugs
- Published on Sunday, 09 November 2014 00:00
- Written by Liz Highleyman
All but 1 participant treated with a coformulation of sofosbuvir and ledipasvir (Harvoni) achieved sustained virological response at 12 weeks post-treatment in a study looking at traditionally hard-to-treat HIV/HCV coinfected patients, researchers reported at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting this week in Boston.
AASLD Liver Meeting Starts this Weekend in Boston
- Details
- Category: Hepatitis B
- Published on Thursday, 06 November 2014 00:00
- Written by HIVandHepatitis.com
The American Association for the Study of Liver Diseases (AASLD) annual Liver Meeting gets underway this weekend, running through November 11 at the Hynes Convention Center in Boston. Once again, this year's meeting will highlight interferon-free direct-acting antiviral regimens for hepatitis C.
FDA Approves Simeprevir + Sofosbuvir Combination for Hepatitis C
- Details
- Category: Experimental HCV Drugs
- Published on Friday, 07 November 2014 00:00
- Written by Janssen
The U.S. Food and Drug Administration (FDA) this week announced additional approval of interferon-free oral therapy for chronic hepatitis C combining Janssen's HCV protease inhibitor simeprevir (Olysio) plus Gilead Sciences' HCV polymerase inhibitor sofosbuvir (Sovaldi), both of which were approved separately in late 2013.
IDWeek 2014: AbbVie 3D HCV Regimen Well-tolerated in PEARL Trials
- Details
- Category: Experimental HCV Drugs
- Published on Wednesday, 15 October 2014 00:00
- Written by Liz Highleyman
AbbVie's 3D hepatitis C regimen containing paritaprevir (ABT-450), ombitasvir, and dasabuvir was generally well-tolerated in the Phase 3 PEARL trials, according to a pooled analysis presented at IDWeek 2014 last week in Philadelphia. Serious side effects were uncommon and few people discontinued treatment for this reason.
Web Design and Development by